A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials
Laura Fertitta,Christina Bergqvist,Kavita Y Sarin,Scott R Plotkin,Christopher Moertel,Andrea K Petersen,Ashley Cannon,Yemima Berman,Dominique C Pichard,Class Röhl,Andres Lessing,Bernadette Brizion,Bastien Peiffer,Philippe Ravaud,Viet-Thi Tran,Marie-Laure Armand,Sabine Moryousef,Salah Ferkal,Arnaud Jannic,Khaled Ezzedine,Pierre Wolkenstein,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) international collaboration,Sarah Adsit,Shivani Ahlawat,Krizelle Alcantara,Rosemary Anderson,Kara Anstett,Lisa Aouad,Rob Avery,Carolina Barnett-Tapia,Belinda Barton,Catherine Batlle,David Bedwell,Tammy Benson O'Brian,Dale Berg,Chetan Bettegowda,Jaishri Blakeley,Rob Brainin,Sara Brebbia Dirksen,Frank Buono,Susan Buono,Wenli Cai,Cynthia Campen,Kelly Carpenter,Alexandra Cellucci,Nicolas Champollion,Long-Shen Chang,Peter de Blank,Allison Del Castillo,Laura Didier,Eva Dombi,Gregg Erickson,Gareth Evans,Onno Faber,Michael Fisher,Barbara Franklin,Edith Garrett,Madalyn Gibson-Williams,Marco Giovannini,Dani Glad,Deborah Gold,Adam Goodkind,Kayo Goto,Jane Grabowski,Vito Grasso,Andrea Gross,Lorenza Grotti,David Gutmann,Diana Haberkamp,Kristine Haebich,Cindy Hahn,Oliver Hanemann,Cynthia Hingtgen,Matt Hocking,Eric Hunt,Maureen Hussey,Kelly Janke,Jennifer Janusz,Justin Jordan,Valerie Kaer,Matthias Karajannis,Kim Keeling,Bob Kesterson,Aerang Kim,Hannah Kim,Yoori Kim,Bonnie Klein-Tasman,Laura Klesse,Kimberley Koetsier,Edina Komlodi-Pasztor,Noelle Larson,Andre Leier,Erica Leif,Robert Listernick,Elana Loftspring,Sharon Loftspring,K Ina Ly,Linda Manth,Staci Martin,Sherri McKnight,Miranda McManus,Vanessa Merker,Elizabeth Morehouse,Irene Moss,Lara Mukabenov,Patricia Newman,Beverly Oberlander,Jonathan Payne,Drea Peterson,Dominque Pichard,Rene Pierpoint,Scott Plotkin,Dorothy Pope,Linda Popplewell,Natalie Pride,Marcus Ratley,Steven Rhodes,Jonathan Rios,Inka Ristow,Bill Riter,Claas Rohl,Carlos Romo,Adam Rosenberg,Tena Rosser,Jessica Samblanet,Kavita Sarin,Herb Sarnoff,Natalie Schneider,Elizabeth Schorry,Mary Sell,Steven Sheard,Dani Silverman,Brittany Simpson,Melissa Smith,Connie Sorman,Verena Staedtke,Pete Stavinoha,Anat Stemmer-Rachamimov,David Stevenson,Taylor Sundby,Heather Thompson,Nicole Ullrich,Meena Upadhyaya,Marjan van de Vrie,Dave Viskochil,Jeremie Vitte,James Walker,Jo Wallace,Deann Wallis,Karin Walsh,Shannon Weaver,Hannah Weisman,Bradley Welling,Brigitte Widemann,Tracy Wirtanen,Pamela Wolters,Mary Achtziger Wong,Jiangbing Zhou
DOI: https://doi.org/10.1093/bjd/ljad397
2024-01-23
Abstract:Background: Cutaneous neurofibromas (cNF) are considered one of the highest burdens of neurofibromatosis type 1 (NF1). To date, no medical treatment can cure cNF or prevent their development. In that context, there is an urgent need to prepare and standardize the methodology of future trials targeting cNF. Objectives: The objective was to develop a core outcome domain set suitable for all clinical trials targeting NF1-associated cNF. Methods: The validated approach of this work consisted of a three-phase methodology: (i) generating the domains [systematic literature review (SLR) and qualitative studies]; (ii) agreeing (three-round international e-Delphi consensus process and working groups); and (iii) voting. Results: (i) The SLR and the qualitative studies (three types of focus groups and a French e-survey with 234 participants) resulted in a preliminary list of 31 candidate items and their corresponding definitions. (ii) A total of 229 individuals from 29 countries participated in the first round of the e-Delphi process: 71 patients, relatives or representatives (31.0%), 130 healthcare professionals (HCPs, 56.8%) and 28 researchers, representatives of a drug regulatory authority, industry or pharmaceutical company representatives or journal editors (12.2%). The overall participation rate was 74%. After round 2, five candidate items were excluded. Between rounds 2 and 3, international workshops were held to better understand the disagreements among stakeholders. This phase led to the identification of 19 items as outcome subdomains. (iii) The items were fused to create four outcome domains ('clinical assessment', 'daily life impact', 'patient satisfaction' and 'perception of health') and prioritized. The seven items that did not reach consensus were marked for the research agenda. The final core outcome domain set reached 100% of the votes of the steering committee members. Conclusions: Although numerous outcomes can be explored in studies related to cNF in NF1, the present study offers four outcome domains that should be reported in all trial studies, agreed on by international patients, relatives and representatives of patients; HCPs; researchers, representatives of drug regulatory authorities or pharmaceutical companies and journal editors. The next step will include the development of a set of core outcome measurement instruments to further standardize how these outcomes should be assessed.